Qingdao Vland Biotech Future Growth
Future criteria checks 1/6
Qingdao Vland Biotech is forecast to grow earnings and revenue by 12.8% and 7.5% per annum respectively. EPS is expected to grow by 12.3% per annum. Return on equity is forecast to be 5.7% in 3 years.
Key information
12.8%
Earnings growth rate
12.3%
EPS growth rate
Biotechs earnings growth | 34.1% |
Revenue growth rate | 7.5% |
Future return on equity | 5.7% |
Analyst coverage | Low |
Last updated | 10 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,527 | 119 | 165 | 278 | 3 |
12/31/2025 | 1,396 | 106 | 77 | 271 | 3 |
12/31/2024 | 1,284 | 94 | 175 | 197 | 3 |
3/31/2024 | 1,253 | 83 | -32 | 127 | N/A |
12/31/2023 | 1,199 | 81 | -62 | 154 | N/A |
9/30/2023 | 1,213 | 71 | -56 | 106 | N/A |
6/30/2023 | 1,175 | 64 | -81 | 100 | N/A |
3/31/2023 | 1,140 | 62 | -114 | 120 | N/A |
12/31/2022 | 1,163 | 70 | -247 | 95 | N/A |
9/30/2022 | 1,148 | 92 | -333 | 50 | N/A |
6/30/2022 | 1,134 | 109 | -447 | 89 | N/A |
3/31/2022 | 1,141 | 122 | -501 | 81 | N/A |
12/31/2021 | 1,151 | 133 | -404 | 90 | N/A |
9/30/2021 | 1,100 | 130 | -288 | 164 | N/A |
6/30/2021 | 1,078 | 126 | -191 | 166 | N/A |
3/31/2021 | 1,030 | 116 | -103 | 179 | N/A |
12/31/2020 | 960 | 109 | -39 | 173 | N/A |
9/30/2020 | 922 | 103 | -57 | 145 | N/A |
6/30/2020 | 884 | 89 | -46 | 97 | N/A |
3/31/2020 | 870 | 89 | -35 | 79 | N/A |
12/31/2019 | 847 | 78 | -55 | 65 | N/A |
9/30/2019 | 840 | 79 | 2 | 101 | N/A |
6/30/2019 | 824 | 81 | 12 | 90 | N/A |
3/31/2019 | 808 | 84 | 36 | 122 | N/A |
12/31/2018 | 814 | 83 | 14 | 86 | N/A |
9/30/2018 | 805 | 86 | 1 | 95 | N/A |
12/31/2017 | 799 | 86 | N/A | 122 | N/A |
12/31/2016 | 781 | 83 | N/A | 154 | N/A |
12/31/2015 | 752 | 70 | N/A | 74 | N/A |
12/31/2014 | 728 | 53 | N/A | 59 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603739's forecast earnings growth (12.8% per year) is above the savings rate (2.9%).
Earnings vs Market: 603739's earnings (12.8% per year) are forecast to grow slower than the CN market (22.1% per year).
High Growth Earnings: 603739's earnings are forecast to grow, but not significantly.
Revenue vs Market: 603739's revenue (7.5% per year) is forecast to grow slower than the CN market (13.6% per year).
High Growth Revenue: 603739's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603739's Return on Equity is forecast to be low in 3 years time (5.7%).